BLI VS ADVM Stock Comparison
Performance
BLI10/100
10/100
BLI returned -83.56% in the last 12 months. Based on the other stocks in it's sector with an average return of -31.49%, it's performance is below average giving it a grade of 10 of 100.
ADVM100/100
100/100
ADVM returned 23.00% in the last 12 months. Based on SPY's performance of 13.09%, its performance is above average giving it a score of 100 of 100.
Forecast
BLI75/100
75/100
5 analysts offer 12-month price forecasts for BLI. Together, they have an average target of 0, the most optimistic forecast put BLI at 0 within 12-months and the most pessimistic has BLI at 0.
ADVM
"Forecast" not found for ADVM
Sentiment
BLI62/100
62/100
BLI had a bullish sentiment score of 62.13% across Twitter and StockTwits over the last 12 months. It had an average of 5.53 posts, 0.77 comments, and 1.49 likes per day.
ADVM65/100
65/100
ADVM had a bullish sentiment score of 65.44% across Twitter and StockTwits over the last 12 months. It had an average of 2.59 posts, 0.41 comments, and 3.22 likes per day.
Technicals
BLI11/100
11/100
BLI receieves a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.
ADVM10/100
10/100
ADVM receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
BLI10/100
10/100
BLI has missed earnings 7 times in the last 20 quarters.
ADVM10/100
10/100
ADVM has missed earnings 9 times in the last 20 quarters.
Profit
BLI10/100
10/100
Out of the last 10 quarters, BLI has had 0 profitable quarters and has increased their profits year over year on 0 of them.
ADVM10/100
10/100
Out of the last 20 quarters, ADVM has had 0 profitable quarters and has increased their profits year over year on 0 of them.
Volatility
BLI42/100
42/100
BLI has had a lower than average amount of volatility over the last 12 months giving it a grade of 42 of 100.
ADVM52/100
52/100
ADVM has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
Analyst Price Targets
BLI
"Analyst Price Targets" not found for BLI
ADVM67/100
67/100
3 analysts offer 12-month price targets for ADVM. Together, they have an average target of 2, the most optimistic target put ADVM at 2 within 12-months and the most pessimistic has ADVM at 2.
All score calculations are broken down here to help you make more informed investing decisions
Berkeley Lights, Inc. Common Stock Summary
Nasdaq / BLI
Healthcare
Biotechnology
Berkeley Lights, Inc., a digital cell biology company, focuses on enabling and accelerating the rapid development and commercialization of biotherapeutics and other cell-based products. The company offers an integrated platform, which comprise of proprietary consumables, including OptoSelect chips and reagent kits, automation systems, and application and workflow software. It serves in North America, the Asia Pacific, and Europe. Berkeley Lights, Inc. was incorporated in 2011 and is headquartered in Emeryville, California.
Adverum Biotechnologies, Inc. Common Stock Summary
Nasdaq / ADVM
Healthcare
Biotechnology
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare BLI to other companies in the same or a similar industry.
